Kura Oncology (KURA) Other Accumulated Expenses (2015 - 2026)

Kura Oncology (KURA) has 12 years of Other Accumulated Expenses data on file, last reported at $3.6 million in Q1 2026.

• Other Accumulated Expenses for Q1 2026 came in at $3.6 million, up 3.18% year-over-year; the trailing twelve-month figure through Mar 2026 was $3.6 million (up 3.18% YoY), and the FY2025 annual result was $3.4 million, up 25.17% from the prior year.
• Other Accumulated Expenses advanced to $3.6 million in Q1 2026 per KURA's latest filing, from $3.4 million in the prior quarter.
• Over five years, Other Accumulated Expenses peaked at $6.3 million in Q3 2025 and troughed at $1.3 million in Q4 2023.
• A 5-year average of $2.8 million and a median of $2.5 million in 2022 frame the typical range for Other Accumulated Expenses.
• The sharpest annual moves came in 2023 and 2025: Other Accumulated Expenses slumped 46.55% in 2023, then soared 154.36% in 2025.
• A 5-year view of Other Accumulated Expenses shows it stood at $2.4 million in 2022, then tumbled by 46.55% to $1.3 million in 2023, then surged by 108.14% to $2.7 million in 2024, then climbed by 25.17% to $3.4 million in 2025, then advanced by 6.1% to $3.6 million in 2026.
• Business Quant data shows KURA's Other Accumulated Expenses at $3.6 million in Q1 2026, $3.4 million in Q4 2025, and $6.3 million in Q3 2025.